A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity

Bibliography

• Ulozas E. Amphotericin B-induced nephrotoxicity. Compr Toxicol 2010;7:347–57
   Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308–29
   PubMedGoogle Scholar
• Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;111:528–34
   PubMed Web of Science ®Google Scholar
• Laniado-Laborı´n R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol 2009;26:223–7
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686–93
   PubMed Web of Science ®Google Scholar
• Karimzadeh I, Farsaei S, Khalili H, et al. Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity? Expert Opin Drug Saf 2012;11:969–83
   PubMed Web of Science ®Google Scholar
• Karimzadeh I, Khalili H, Farsaei S, et al. Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity. Eur J Clin Pharmacol 2013;69:1351–68
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006;15:105–10
   PubMed Web of Science ®Google Scholar
• Hosseinjani H, Moghaddas A, Khalili H. N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence. Eur J Clin Pharmacol 2013;69:1375–90
   PubMed Web of Science ®Google Scholar
• KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012.2(Suppl 1):8. Available from: www.kdigo.org/clinical...guidelines/.../KDIGO%20AKI%20Guideline [Last accessed 11 August 2012]
   Google Scholar
• Feldman L, Efrati S, Dishy V, et al. N-acetylcysteine ameliorates amphotericin-induced nephropathy in rats. Nephron Physiol 2005;99:23–7
   Google Scholar
• Odabasi Z, Karaalp A, Cermik H, et al. Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine. Antimicrob Agents Chemother 2009;53:3100–2
   PubMed Web of Science ®Google Scholar
• Pianta TJ, Buckley NA, Peake PW, et al. Clinical use of biomarkers for toxicant-induced acute kidney injury. Biomark Med 2013;7:441–56
   PubMed Web of Science ®Google Scholar
• Smith SR, Galloway MJ, Reilly JT, et al. Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients. J Clin Pathol 1988;41:494–7
   PubMed Web of Science ®Google Scholar
• Ural AU, Avcu F, Cetin T, et al. Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients? Eur J Clin Pharmacol 2002;57:771–3
   PubMed Web of Science ®Google Scholar
• KDOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Available from: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm [Last accessed 11 August 2012]
   Google Scholar
• Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 2004;26:421–6
   PubMed Web of Science ®Google Scholar
• Clarkson MR, Friedewald JJ, Eustace JA, Rabb BM. Acute kidney injury. In: Brenner BM. 8th edition. Brenner and Rector's The Kidney; Philadelphia, Pa: Saunders Elsevier; 2007: chap 29.
   Google Scholar
• Karimzadeh I, Khalili H, Dashti-Khavidaki S, et al. N-acetyl cysteine in prevention of amphotericin- induced electrolytes imbalances: a randomized, double-blinded, placebo-controlled, clinical trial. Eur J Clin Pharmacol 2014;70:399–408
   PubMed Web of Science ®Google Scholar
• Hernandez MD, Mansouri MD, Aslam S, et al. Efficacy of combination of N-acetylcysteine, gentamicin, and amphotericin B for prevention of microbial colonization of ventricular assist devices. Infect Control Hosp Epidemiol 2009;30:190–2
   PubMed Web of Science ®Google Scholar
• Forrest JM, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels. Pharmactuel 2014;47:161–5
   Google Scholar
• Rudnick MR. Prevention of contrast-induced nephropathy. In: UpToDate. Post TW, Editors UpToDate; Waltham, MA: 2013
   Google Scholar
• Lynch RM, Robertson R. Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study. Accid Emerg Nurs 2004;12:10–15
   PubMedGoogle Scholar
• Appelboam AV, Dargan PI, Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. Emerg Med J 2002;19:594–5
   PubMed Web of Science ®Google Scholar
• Inselmann G, Balaschke M, Heidemann HT. Enzymuria following amphotericin B application in the rat. Mycoses 2003;46:169–73
   PubMed Web of Science ®Google Scholar
• Tonomura Y, Yamamoto E, Kondo C, et al. Amphotericin B-induced nephrotoxicity: characterization of blood and urinary biochemistry and renal morphology in mice. Hum Exp Toxicol 2009;28:293–300
   PubMed Web of Science ®Google Scholar
• Kondo C, Aoki M, Yamamoto E, et al. Predictive genomic biomarkers for drug-induced nephrotoxicity in mice. J Toxicol Sci 2012;37:723–37
   PubMed Web of Science ®Google Scholar
• Pai MP, Norenberg JP, Telepak RA, et al. Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate. Antimicrob Agents Chemother 2005;49:3784–8
   PubMed Web of Science ®Google Scholar
• Demirtaş S, Akan O, Can M, et al. Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem 2006;39:115–18
   PubMed Web of Science ®Google Scholar
• Duan SB, Liu GL, Yu ZQ, et al. Urinary KIM-1, IL-18 and Cys-c as early predictive biomarkers in gadolinium-based contrast-induced nephropathy in the elderly patients. Clin Nephrol 2013;80:349–54
   PubMed Web of Science ®Google Scholar
• Tsigou E, Psallida V, Demponeras C, et al. Role of new biomarkers: functional and structural damage. Crit Care Res Pract 2013;2013:361078
   PubMedGoogle Scholar
• Ribichini F, Gambaro G, Graziani MS, et al. Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. Clin Chem 2012;58:458–64
   PubMed Web of Science ®Google Scholar
• Piccioni M, Al-Ismaili Z, Devarajan P. Biomarkers of cisplatin and ifosfamide nephrotoxicity in children. J Am Soc Nephrol 2011;22:360A
   Google Scholar
• McWilliam SJ, Antoine DJ, Sabbisetti V, et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS One 2012;7:e43809
   PubMed Web of Science ®Google Scholar